Biotec Pharmacon ASA appoints Dr. Jethro Holter as interim CEO
(Tromsø/Oslo 23. October 2019) Biotec Pharmacon ASA (OSE: “BIOTEC”) announced today that its Board of Directors has unanimously appointed Dr Jethro Holter as the Company’s interim Chief Executive Officer. Jethro, who currently serves as the Managing Director of ArcticZymes AS, a subsidiary of Biotec Pharmacon, will succeed Christian Jorgensen, the current CEO, effective immediately.
Jethro joined ArcticZymes as Managing Director in January 2015. He focused on driving a new strategic direction focusing the subsidiary’s efforts towards growth, through expanding its B2B client base and implementing a customer-driven innovation approach for new product development. Consequently, the subsidiary has experienced strong revenue growth and vastly expanded its portfolio of novel enzyme products. Today, ArcticZymes is profitable and a leading commercial supplier of enzymes to the molecular biology, In Vitro Diagnostics (IVD) and gene therapy market segments.
‘We are delighted to appoint Jethro as our interim CEO. He has proven himself to be a strong and highly competent leader who has the skill-set required to take Biotec Pharmacon to the next level” said Dr Marie Roskrow, Chairman of the Board of Directors. “The Board of Directors looks forward to working closely with Jethro and the management team to focus the Company’s efforts on the value-driving and high-growth areas of the business in order to achieve sustainable profitability and value for our shareholders”.
Jethro has previous experience in international business development, R&D and sales from Life Technologies (Thermo Fisher Scientific), Mole Genetics AS, Pfizer Ltd and other institutions. Jethro holds a Ph.D in Molecular Neuroscience from Cardiff University, UK.
The Board would like to thank Christian for his service to the Company during the past two years and the changes he made to the business. We wish him good luck with his future endeavours.
As a consequence of the current changes, Biotec Pharmacon will not hold a Q3 2019 presentation tomorrow morning on Thursday 24. Oct. 2019. The Q3 2019 financial report will be published according to plan.
For further information, please contact:
Dr. Marie Roskrow
Chairman of the Board
Mobile: +44 (0) 7496 959743
Landline: + 44 1278 662782